Feature Channels: Immunology

Filters close
Released: 5-Jan-2024 2:05 PM EST
Major breakthrough unveils immune system's guardian: IKAROS
Monash University

In a scientific breakthrough that aids our understanding of the internal wiring of immune cells, researchers at Monash University in Australia have cracked the code behind IKAROS, an essential protein for immune cell development and protection against pathogens and cancer.

Newswise: Immunotherapy for metastatic cancer on the rise, even near end of life
Released: 4-Jan-2024 12:05 PM EST
Immunotherapy for metastatic cancer on the rise, even near end of life
Yale Cancer Center/Smilow Cancer Hospital

A new study led by Yale Cancer Center researchers at Yale School of Medicine found that while the initiation of immunotherapy near the end of life has increased over time, a closer look at the benefit and value of these therapies in patients with advanced-stage disease is needed.

Newswise: Immune cell helps predict skin cancer patients’ chances of responding to treatment
Released: 3-Jan-2024 5:05 PM EST
Immune cell helps predict skin cancer patients’ chances of responding to treatment
King's College London

A type of immune cell can help predict which patients may benefit most from cancer immunotherapies, researchers from King’s College London, Guy’s and St Thomas’ Hospital Trust, and the Francis Crick Institute have found.

Newswise:Video Embedded what-the-pandemic-is-teaching-us-about-the-immune-system
VIDEO
Released: 3-Jan-2024 10:05 AM EST
What the Pandemic Is Teaching Us About the Immune System
Harvard Medical School

Novel insights from the pandemic may be propelling the field of immunology into a new golden age.

Released: 2-Jan-2024 4:05 PM EST
دراسة تظهر أن الجزيئات المناعية قد يكون لها دورًا رئيسيًا في تطور مرض التصلُّب الجانبي الضموري (ALS)
Mayo Clinic

حدد الباحثون والمتعاونون في مايو كلينك بروتينًا تفرزه الخلايا المناعية والذي قد يقوم بدورٍ رئيسيٍ في ظهور مرضالتصلُّب الجانبي الضموري، المعروف أيضًا باسم مرض لو غيريغ. ووجد الفريق أيضًا أن العلاج التعديلي المناعي الذي يقوم بعملية إِحْصار للبروتين يمكنه استعادة الوظيفة الحركية في النماذج قبل السريرية. وتشير النتائج إلى أن البروتين، المعروف باسم أ5 إنتغرين (الذي يُنطق ألفا 5 إنتغرين)، هو مستهدف علاجي محتمل لعلاج مرض التصلُّب الجانبي الضموري.

Released: 2-Jan-2024 3:05 PM EST
Un estudio muestra que una molécula del sistema inmunitario puede desempeñar un rol clave en la evolución de la ELA
Mayo Clinic

Los investigadores y colaboradores de Mayo Clinic han identificado una proteína expresada en células inmunitarias que podría desempeñar un rol clave en el desarrollo de la esclerosis lateral amiotrófica (ELA), también conocida como enfermedad de Lou Gehrig. El equipo también descubrió que un tratamiento inmunomodulatorio que bloquea la proteína era capaz de restaurar la función motriz en modelos preclínicos. Los hallazgos indican que la proteína, conocida como integrina α5 (pronunciado integrina alfa 5), es un posible blanco terapéutico para la ELA.

Released: 2-Jan-2024 3:05 PM EST
Estudo mostra que molécula imunológica pode desempenhar uma função fundamental na progressão da ELA
Mayo Clinic

Pesquisadores e colaboradores da Mayo Clinic identificaram uma proteína que é expressa por células imunológicas que pode desempenhar uma função importante no desenvolvimento daesclerose lateral amiotrófica (ELA), também conhecida como doença de Lou Gehrig. A equipe também descobriu que um tratamento imunomodulador que bloqueia a proteína conseguiu restaurar a função motora em modelos pré-clínicos. As descobertas sugerem que a proteína, conhecida como integrina α5 (pronunciada como integrina alfa 5), é um possível alvo terapêutico para ELA.

Newswise: Predicting Lymphoma Patients’ Treatment Outcomes
Released: 21-Dec-2023 10:05 AM EST
Predicting Lymphoma Patients’ Treatment Outcomes
Cedars-Sinai

Cedars-Sinai Cancer investigators have discovered a new way to predict whether a cancer of the immune system will recur in patients treated with a bone marrow transplant.

Released: 20-Dec-2023 3:05 PM EST
Working with Big Data requires a lot of power! The latest research and features on Supercomputing
Newswise

With the rise in machine learning applications and artificial intelligence, it's no wonder that more and more scientists and researchers are turning to supercomputers. Supercomputers are commonly used for making predictions with advanced modeling and simulations. This can be applied to climate research, weather forecasting, genomic sequencing, space exploration, aviation engineering and more.

       
Newswise: Cancer Research Institute Joins Lance Kawaguchi, #SouthPoleTrek4Cancer to Ring the Nasdaq Stock Market Closing Bell
Released: 19-Dec-2023 10:15 AM EST
Cancer Research Institute Joins Lance Kawaguchi, #SouthPoleTrek4Cancer to Ring the Nasdaq Stock Market Closing Bell
Cancer Research Institute

The Cancer Research Institute and Lance Kawaguchi with the #SouthPoleTrek4Cancer ring in the Nasdaq Stock Market Closing Bell.

Released: 18-Dec-2023 9:30 PM EST
Toothbrushing tied to lower rates of pneumonia among hospitalized patients
Brigham and Women’s Hospital

Researchers have found an inexpensive tool that may help reduce rates of pneumonia for hospitalized patients—and it comes with bristles on one end.

Newswise: NUS researchers develop an innovative and flexible method to study immune cell capabilities
Released: 17-Dec-2023 9:05 PM EST
NUS researchers develop an innovative and flexible method to study immune cell capabilities
National University of Singapore (NUS)

Researchers from the National University of Singapore (NUS) devise a simple and innovative way to directly identify and sort the immune cells involved in cell-mediated cytotoxicity.

Released: 15-Dec-2023 9:30 PM EST
Immune cells shape lung before birth and provide new avenues for treating respiratory diseases
Wellcome Trust Sanger Institute

Immune cells play an active and intimate role in directing the growth of human lung tissue during development, researchers find, revolutionising our understanding of early lung development and the role of immune cells outside of immunity.

Released: 15-Dec-2023 12:30 PM EST
Novel therapeutic target overcomes resistance to radiation therapy
University of Chicago Medical Center

UChicago Medicine researchers discover that restoring BAMBI to normal levels in immune suppressive cells can overcome resistance to radiation therapy.

Released: 15-Dec-2023 9:30 AM EST
How the Immune System Fights to Keep Herpes at Bay
Harvard Medical School

Using lab-made cells, Harvard Med researchers identify how the immune system neutralizes herpesvirus. Study maps, for the first time, the maneuvers used by virus and host in the cell nucleus. Findings could inform design of new treatments for herpes and other viruses that replicate in the same way.

Released: 14-Dec-2023 7:05 AM EST
Rakuten Medical to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10th, 2024
Rakuten Medical, Inc.

Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell-targeting photoimmunotherapy treatments based on its proprietary Alluminox™ platform, today announced that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference being held January 8-11, 2024.

Newswise: Liquid Biopsy Predicts Immunotherapy Response and Toxicity in Patients with Advanced Lung Cancer
Released: 12-Dec-2023 11:00 AM EST
Liquid Biopsy Predicts Immunotherapy Response and Toxicity in Patients with Advanced Lung Cancer
Johns Hopkins Medicine

By monitoring changes in circulating tumor DNA (ctDNA) among 30 patients treated with immunotherapies for metastatic non-small cell lung cancers, researchers were able to determine molecular response — the clearance of tumor genetic material in the bloodstream.

Newswise: Combination immunotherapy produces high response rate in early results of Sylvester trial targeting high-risk follicular lymphoma
4-Dec-2023 8:30 PM EST
Combination immunotherapy produces high response rate in early results of Sylvester trial targeting high-risk follicular lymphoma
Sylvester Comprehensive Cancer Center

Researchers conducting a Phase 2 clinical trial at Sylvester Comprehensive Cancer Center say a new combination of antibody therapies produced a ‘surprisingly high’ response rate in patients with high-risk follicular lymphoma, a type of non-Hodgkin lymphoma.

11-Dec-2023 9:45 AM EST
Wayne State University study reports progress in long-term protection against ovarian cancer tumors
Wayne State University Division of Research

Investigators from the C.S. Mott Center for Human Growth and Development at the Wayne State University School of Medicine reported today in a publication in Cancer Immunology Research the characterization of a novel therapeutic approach capable of restoring immune surveillance and providing long-term protection against ovarian cancer tumors.

Newswise: Cell Therapy Appears Safe and Effective for Lymphoma in Remission
5-Dec-2023 9:05 PM EST
Cell Therapy Appears Safe and Effective for Lymphoma in Remission
Sylvester Comprehensive Cancer Center

A study led by researchers at Sylvester Comprehensive Cancer Center suggests that CAR-T immunotherapy remains a viable option for patients who have lymphoma that goes into remission before the cell therapy begins. Downloadable video is available.

Released: 9-Dec-2023 10:05 AM EST
Structure of a central component of the human immune system revealed
Ludwig-Maximilians-Universität München (Munich)

An international team of researchers from LMU and the Helmholtz Centre for Infection Research has visualized the structure of the so-called ASC speck.

Newswise: COVID-19: The persistence of SARS-CoV-2 in the lungs and the role of innate immunity
Released: 8-Dec-2023 1:05 PM EST
COVID-19: The persistence of SARS-CoV-2 in the lungs and the role of innate immunity
Institut Pasteur

One to two weeks after contracting COVID, the SARS-CoV-2 virus generally becomes undetectable in the upper respiratory tract. But does that mean that it is no longer present in the body? To find out, a team from the Institut Pasteur specialized in HIV, in collaboration with a French public research institute, the Alternative Energies and Atomic Energy Commission (CEA), conducted a study on lung cells in an animal model.

Newswise: T cells tackle new 'Pirola' SARS-CoV-2 variant
7-Dec-2023 5:05 PM EST
T cells tackle new 'Pirola' SARS-CoV-2 variant
La Jolla Institute for Immunology

According to new predictions by La Jolla Institute for Immunology (LJI) researchers, if the new SARS-CoV-2 Pirola variant wants to evade T cells, it isn't doing a very good job.

   
Released: 7-Dec-2023 6:05 PM EST
Cancer therapy bexmarilimab awakens immune cells to attack tumours that have avoided the detection of the immune system
University of Turku (Turun yliopisto)

Researchers at the University of Turku, Finland, have uncovered how the new bexmarilimab therapy alters the function of immune cells so that they can infiltrate the tumour in cancer patients who do not respond to any other current therapies.

Released: 7-Dec-2023 5:05 PM EST
New method is better able to map immune response and paves way for new treatments
Karolinska Institute

Immune cells such as T and B cells are central to the body’s defence against both infections and tumours.

Released: 7-Dec-2023 1:30 PM EST
Lessons Learned From ADLM’s COVID Immunity Study Could Improve Research on Future Pandemics
Association for Diagnostic and Laboratory Medicine (ADLM (formerly AACC))

A special report published today in the Association for Diagnostics & Laboratory Medicine’s (ADLM’s, formerly AACC’s) The Journal of Applied Laboratory Medicine describes the design, operations, and methodology of the COVID Immunity Study, a large-scale scientific study by ADLM that took place in September 2021.

Newswise: Tiny bubbles could reveal immune cell secrets and improve treatments
Released: 7-Dec-2023 12:05 PM EST
Tiny bubbles could reveal immune cell secrets and improve treatments
Penn State Materials Research Institute

Realizing the full potential of macrophage therapies relies on being able to see what these cellular allies are doing inside our bodies, and a team of Penn State researchers may have developed a way to watch them do their thing.

Newswise: Researchers redesign future mRNA therapeutics to prevent potentially harmful immune responses
Released: 6-Dec-2023 6:05 PM EST
Researchers redesign future mRNA therapeutics to prevent potentially harmful immune responses
University of Cambridge

Researchers have discovered that misreading of therapeutic mRNAs by the cell’s decoding machinery can cause an unintended immune response in the body. They have identified the sequence within the mRNA that causes this to occur and found a way to prevent ‘off-target’ immune responses to enable the safer design of future mRNA therapeutics.

Released: 6-Dec-2023 2:05 PM EST
Influx of water and salts propel immune cells through the body
Francis Crick Institute

Researchers at the Francis Crick Institute, working with Imperial College London, King’s College London and University of Cambridge, have shown that an influx of water and ions into immune cells allows them to migrate to where they’re needed in the body.

Newswise: Type 1 diabetes: B cell-derived natural antibodies suppress autoimmune pathogenesis
Released: 6-Dec-2023 5:05 AM EST
Type 1 diabetes: B cell-derived natural antibodies suppress autoimmune pathogenesis
University of Alabama at Birmingham

Researchers have discovered the novel mechanism that underlies a previously reported observation that infection by group A Streptococcus bacteria reduces the risk of later developing Type 1 diabetes.

30-Nov-2023 11:05 AM EST
Depression, Constipation, and Urinary Tract Infections May Precede MS Diagnosis
American Academy of Neurology (AAN)

In some diseases, the underlying processes can start years before a diagnosis is made. A new study finds that people who later develop multiple sclerosis (MS) are more likely to have conditions like depression, constipation and urinary tract infections five years before their MS diagnosis than people who do not develop MS.

Newswise: Training the immune system to prevent cancer – NextGen researchers discover paradigm-shifting approach
Released: 4-Dec-2023 6:05 PM EST
Training the immune system to prevent cancer – NextGen researchers discover paradigm-shifting approach
University of Missouri, Columbia

As one of the most insidious diseases in the world, cancer has few treatments that work to eradicate it completely. Now, a new ground-breaking approach pioneered by two researchers working at the University of Missouri’s Roy Blunt NextGen Precision Health building shows promising results in preventing lung cancer caused by a carcinogen in cigarettes — a discovery that immunologists Haval Shirwan and Esma Yolcu rank among the most significant of their careers.

Newswise: Could Our Body’s “Bleach” Be Key to Fighting a Common Fungal Pathogen?
Released: 4-Dec-2023 1:05 PM EST
Could Our Body’s “Bleach” Be Key to Fighting a Common Fungal Pathogen?
Stony Brook University

A study that assesses the effects of hypochlorous acid (HOCI), commonly known as bleach, as it is generated during the immune response of a cell (phagocytosis) when fighting a common fungal pathogen, Candida albicans, reveals that HOCI is a potent killing agent. The laboratory finding is highlighted in the journal mBio.

Released: 4-Dec-2023 11:05 AM EST
Entender el tratamiento con linfocitos T-CAR y sus posibles efectos secundarios
Mayo Clinic

La inmunoterapia aprovecha el sistema inmunitario del organismo para combatir el cáncer. El tratamiento con linfocitos T con receptor quimérico para el antígeno (tratamiento con linfocitos T-CAR) es una forma de inmunoterapia en la que los profesionales de atención médica extraen las células T de una persona (conocidas como linfocitos que participan en la respuesta del sistema inmunitario) y las modifican genéticamente para que produzcan receptores quiméricos para el antígeno. A continuación, estos linfocitos T-CARse reintroducen en el torrente sanguíneo del paciente, donde se dirigen a las células cancerosas y las destruyen.

Released: 1-Dec-2023 4:05 PM EST
فهم العلاج بالخلايا التائية المستقبلة للمستضدات الخيمرية (CAR-T) وآثارها الجانبية المحتملة
Mayo Clinic

العلاج المناعي يسخر جهاز المناعة في الجسم لمحاربة السرطان. العلاج بالخلايا التائية المستقبلة للمستضدات الخيمرية (العلاج بخلايا CAR-T) هو شكل من أشكال العلاج المناعي الذي يقوم فيه أخصائيو الرعاية الصحية بإزالة الخلايا التائية للشخص — خلايا الدم البيضاء المعروفة باسم الخلايا اللمفية التي تشارك في استجابة الجهاز المناعي — وتعديلها وراثيًا لإنتاج مستقبلات المستضد الخيمرية (CARs). يتم بعد ذلك حقن الخلايا التائية المستقبلة للمستضدات الخيمرية (CAR-T) مرة أخرى في مجرى دم المريض، حيث تستهدف الخلايا السرطانية وتقتلها.

Newswise: Research Shows Human Behavior Guided by Fast Changes in Dopamine Levels
Released: 1-Dec-2023 9:05 AM EST
Research Shows Human Behavior Guided by Fast Changes in Dopamine Levels
Wake Forest University School of Medicine

A new study from researchers at Wake Forest University School of Medicine shows that dopamine release in the human brain plays a crucial role in encoding both reward and punishment prediction errors.

Released: 1-Dec-2023 7:05 AM EST
Hope for autoimmune skin disorder sufferers with new immunotherapy strategy
The Peter Doherty Institute for Infection and Immunity

Researchers, led by University of Melbourne’s Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at the Peter Doherty Institute of Infection and Immunity (Doherty Institute), discovered distinct mechanisms controlling different types of immune cells, and found that, by precisely targeting these mechanisms, they could selectively eliminate ‘problematic cells’ and reshape the skin's immune landscape.

Newswise: Eating beans improves gut health, regulates immune and inflammatory processes in colorectal cancer survivors
30-Nov-2023 11:00 AM EST
Eating beans improves gut health, regulates immune and inflammatory processes in colorectal cancer survivors
University of Texas MD Anderson Cancer Center

Incorporating navy beans into the diet of colorectal cancer survivors has the potential to positively impact both gut and host health by modulating markers linked to obesity and disease, according to new research from The University of Texas MD Anderson Cancer Center.

Released: 30-Nov-2023 2:05 PM EST
Fred Hutch at ASH: Gene therapies for sickle cell, how to improve ‘time toxicity’ for multiple myeloma treatments, what makes a ‘perfect’ graft — and much more
Fred Hutchinson Cancer Center

SEATTLE — Nov. 30, 2023 — The 65th Annual Meeting & Exposition of the American Society of Hematology (ASH) will take place in San Diego, Calif. and online Dec. 9-13.Below are highlights of Fred Hutchinson Cancer Center research to be presented and experts available to comment on news.

Released: 30-Nov-2023 2:05 PM EST
Harnessing the power of a parasite that can stop pain
Ohio State University

For the first time, scientists have begun to figure out why the disfiguring skin lesions caused by cutaneous leishmaniasis don’t hurt.

Newswise: November Research Highlights
Released: 30-Nov-2023 11:05 AM EST
November Research Highlights
Cedars-Sinai

A roundup of the latest medical discoveries and faculty news at Cedars-Sinai.

Newswise: Modular chimeric cytokine receptors improve CAR T–cell therapy for solid tumors
Released: 30-Nov-2023 11:05 AM EST
Modular chimeric cytokine receptors improve CAR T–cell therapy for solid tumors
St. Jude Children's Research Hospital

Adding a modular chimeric cytokine receptor to CAR T cells increased their efficacy. Learn how this modular system could improve brain and solid tumor therapy.

   
Released: 28-Nov-2023 11:05 AM EST
Study reveals hidden immune defense against cancer
University of California, Los Angeles (UCLA), Health Sciences

Researchers at the UCLA Jonsson Comprehensive Cancer Center have found certain immune cells can still fight cancer even when the cancer cells lack an important protein that the immune system relies on to help track down cancer cells.

Newswise: Bacteria, stay out!
Released: 28-Nov-2023 3:05 AM EST
Bacteria, stay out!
Empa, Swiss Federal Laboratories for Materials Science and Technology

Hospital germs and pathogens are not always transmitted directly from person to person. They can also spread via germ-contaminated surfaces and objects.

Newswise: Can a Novel Approach Lead to Less-Toxic Treatments for Leukemia?
Released: 27-Nov-2023 9:05 PM EST
Can a Novel Approach Lead to Less-Toxic Treatments for Leukemia?
Children's Hospital Los Angeles

Traditional cancer treatments such as chemotherapy and radiation can come with collateral damage. In the process of killing cancer, the treatments harm normal cells, too, leading to both short- and long-term side effects. Even today’s targeted drugs and immunotherapy can have effects on normal tissues.



close
1.85981